| **DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION** | **DRUG TYPE AND USE** | **LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION** | **PBAC OUTCOME** |
| --- | --- | --- | --- |
| METHOXSALENSolution for blood fraction, 20 microgram per mL, 10 mLUvadex®Terumo BCT Australia Pty LtdNew listing(Major Submission) | Erythrodermic cutaneous T-cell lymphoma | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (STREAMLINED) listing for the treatment of patients with advanced stage, erythrodermic cutaneous T-cell lymphoma under certain conditions, as part of treatment with integrated, closed system, extracorporeal photopheresis. | The PBAC recommendation cannot be made public until the TGA outcome is known. |